Work

EDITORIAL

Year: 2006
Type: editorial
Abstract: At the time of going to press, we were informed of our second impact factor that now is 1.264. Although still low by international standards it is gratifying to see it increased by 36% and we remain committed to a similar or greater improvement each year. I am sure you will be pleased with this result and we would like to take this opportunity to thank everyone for their contribution to Respirology and to its success. Over the last year, we have noticed a significant improvement in the quality and number of manuscripts submitted to the Journal and our referees and Associate Editors have greatly helped raise the standard of manuscripts accepted by the Journal. We are trying to position the Journal to bridge the laboratory to the clinic and as such would welcome more basic science articles. We are looking forward to another successful year working together. As is a tradition in Respirology, we are delighted to present a Guest Editorial by one of our new Associate Editors and a very dynamic member of our team, Professor David Hui. David is an Associate Professor and the Head of Division of Respiratory Medicine at The Chinese University of Hong Kong. He is a specialist in sleep apnoea, viral pneumonia, in particular SARS and avian influenza, and COPD. David has joined our team in April this year and has already brought many new ideas and initiatives to the Journal. I recommend his editorial, entitled ‘Obstructive sleep apnoea and stroke’ in which the relationship between OSA and vascular complications is discussed and solutions are proposed. In this issue, we continue with our second review from our Presidents’ review series, which represent the transcription of the lecture given by the presidents of the four major respiratory societies, namely, the APSR, ERS, ACCP and ATS at the latest APSR conference in Guangzhou, China. This second review ‘Skeletal muscles in chronic obstructive pulmonary disease: deconditioning, or myopathy?’ has been produced by Professor Peter Wagner, the President of the ATS. In his review, Professor Wagner asks the question of the origin of the muscular loss in COPD patients and suggests some solutions to help those patients. Professor Wagner is Chief of the Division of Pulmonary and Critical Care in the Department of Medicine at the University of California, San Diego, USA. He is a renowned specialist in this field with an impressive track record of publication and involvement in committees and societies. I am sure that this review will be of great interest to all our readers. We continue with our Lung Cancer Review Series with two more reviews in this issue, on the topic of the epidermal growth factor receptor, EGFR, its mutations in lung cancer and the implications for clinical treatment. In the past few years, the role of several tyrosine kinases in signal transduction within cancer cells has been recognized bringing about the development of new drugs targeting tyrosine kinases in order to inhibit signal transduction specifically in cancer cells. The EGFR has been shown to be overexpressed in non-small cell lung cancer and is also involved in promoting cell growth and proliferation; in addition, EGFR signal transduction involves a tyrosine kinase domain, making this receptor a potential target for tyrosine kinase inhibitors. The first paper by Dr Ravi Salgia and his colleague Dr Syed M. Ahmed from the University of Chicago presents a comprehensive review of the latest data on different mutations of the EGFR identified in lung cancer patients and their implications for the sensitivity to different antityrosine kinase drugs in different types of cancer. Dr Salgia has more than 15 years experience in thoracic oncology and has developed a programme assessing novel therapeutic agents targeting the EGFR in lung cancer. The second review by Dr Kato is an up-to-date review on the benefits and risks associated with the clinical use of EGFR inhibitors. I am sure it will be of great value to clinicians among our readers. Dr Kato and his co-author Dr Nishio are from the Shien-Lab and Division of Medical Oncology, National Cancer Centre Hospital in Tokyo, Japan and have interests in the clinical fields of respiratory medicine, thoracic oncology and medical oncology and the research fields of clinical and translational research in the field of clinical trials for the treatment of thoracic malignancy, biomarker studies in clinical trials of molecular and cytotoxic drugs and prediction and treatment of drug-induced interstitial lung disease. I recommend these two very interesting reviews to you. We are pleased to present an invited review by Dr Yew and Dr Leung from the Department of Health in Hong Kong entitled ‘Antituberculosis drugs and hepatotoxicity’ (pp. 699–707). They present a comprehensive review of the immunogenetics and clinical risk factors for drug hepatotoxicity in patients with tuberculosis and propose some management solutions. We would like to thank Dr Yew and Dr Leung for contributing this very interesting review. I recommend this review to all our readers. Also of interest in this issue is the original article by Dr Sugiyama and his colleagues entitled ‘Elevated levels of IP-10 and ENA-78 in patients with pulmonary sarcoidosis’ (pp. 708–714). In this study, the authors have measured the serum and BAL fluid levels of interferon-γ-inducible protein-10 (IP-10) and epithelial neutrophil-activating peptide (ENA)-78 in patients with different stages of sarcoidosis and showed that serum and BAL fluid concentrations of IP-10 and BAL fluid levels of ENA-78 in patients with sarcoidosis were significantly higher than those in control subjects. Moreover, the levels of these markers were associated with different stages of sarcoidosis suggesting that IP-10 may play an important role in regulating lymphocytes into the lung and that ENA-78 may be associated with lung parenchymal disease in pulmonary sarcoidosis. Another highlight in this issue is a manuscript that we have decided to fast-track for publication by Dr Chien and his colleagues entitled ‘Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome’ (pp. 715–722). Based on the observation that pathological changes in severe acute respiratory syndrome (SARS) suggest that SARS sequelae are associated with dysregulation of cytokine and chemokine production, these authors have investigated the temporal changes in cytokine/chemokine profiles in the sera of SARS patients and compared them with those from patients with community-acquired pneumonia (CAP) and according to the severity of lung involvement. They identified the cytokine/chemokine profiles that probably contribute to the main immunopathological processes involved in lung injury in SARS and showed that the changes in these profiles are remarkably different from those observed in CAP patients. This is of great interest for the future management of patients with SARS. Another highlight in this issue is the manuscript by Dr Tan and her colleagues entitled ‘Effectiveness of early budesonide intervention in Caucasian versus Asian patients with asthma: 3-year results of the START study’ (pp. 767–775). This multicentre study investigated the effect of inhaled corticosteroid therapy in Asian patients with asthma and compared with Caucasian patients. The results showed that inhaled budesonide administered once daily in Asian patients with recent-onset, mild persistent asthma significantly improved asthma control and pulmonary function compared with reference therapy. Moreover, this effectiveness paralleled that observed in Caucasian patients. This report will be of great interest in our region. Dr Stephen Stick from Perth, Australia, has announced his retirement from his role of Associate Editor due to increased clinical responsibilities. Dr Stick joined the Journal in June 2001. His contribution as our paediatrics specialist over the past 5 years has been greatly appreciated. We are very grateful for his dedication and commitment to the Journal, and we will miss working with him. He will stay involved with Respirology as an Editorial Board member. We are delighted to announce that Professor Philip Bardin, from Melbourne, Australia has recently joined our team of Associate Editors. Professor Bardin’s interests are in viral infection and asthma and we are looking forward to his contribution to the Journal. I would like to remind you of our new section Journal Statistics, where we report the latest performance of the Journal. We will update this section in each issue to keep you up-to date with our collective performance in producing Respirology. Please note that we have revised and updated our instructions for authors and list of abbreviations. The new instructions are published in this issue and will be implemented in 2007. Of particular interest is the introduction of two new categories of manuscripts that can be submitted to the Journal: Scientific Letters and Medical Hypotheses. We have also made some changes to our general instructions on manuscripts and references format so please read our new instructions carefully before you submit your next manuscript. I hope you enjoy this issue of Respirology.
Source: Respirology
Language: Spanish
Open Access status: bronze
OpenAlex ID: W4237994679
Cites:
Cited by:
Related to: 10